Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary cutaneous, epidermotropic mycosis fungoides-like presentation: critical appraisal and description of two novel cases, broadening the spectrum of ALK+ T-cell lymphoma.
Croci GA, Appio L, Cecchetti C, Tabano S, Alberti-Violetti S, Berti E, Rahal D, Cavallaro F, Onida F, Tomasini D, Todisco E. Croci GA, et al. Among authors: cecchetti c. Virchows Arch. 2024 May 23. doi: 10.1007/s00428-024-03832-6. Online ahead of print. Virchows Arch. 2024. PMID: 38780617
Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum.
Ferreri AJM, Sassone M, Miserocchi E, Govi S, Cecchetti C, Corti ME, Mappa S, Arcaini L, Zaja F, Todeschini G, Mannina D, Calimeri T, Perrone S, Ponzoni M, Modorati G. Ferreri AJM, et al. Among authors: cecchetti c. Blood Adv. 2020 Mar 24;4(6):1013-1019. doi: 10.1182/bloodadvances.2020001459. Blood Adv. 2020. PMID: 32182364 Free PMC article. Clinical Trial.
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
Ferreri AJ, Sassone M, Zaja F, Re A, Spina M, Rocco AD, Fabbri A, Stelitano C, Frezzato M, Rusconi C, Zambello R, Couto S, Ren Y, Arcari A, Bertoldero G, Nonis A, Scarfò L, Calimeri T, Cecchetti C, Chiozzotto M, Govi S, Ponzoni M. Ferreri AJ, et al. Among authors: cecchetti c. Lancet Haematol. 2017 Mar;4(3):e137-e146. doi: 10.1016/S2352-3026(17)30016-9. Epub 2017 Feb 17. Lancet Haematol. 2017. PMID: 28219694 Clinical Trial.
Clarithromycin as a "repurposing drug" against MALT lymphoma.
Ferreri AJM, Cecchetti C, Kiesewetter B, Sassone M, Calimeri T, Perrone S, Ponzoni M, Raderer M. Ferreri AJM, et al. Among authors: cecchetti c. Br J Haematol. 2018 Sep;182(6):913-915. doi: 10.1111/bjh.14878. Epub 2017 Aug 2. Br J Haematol. 2018. PMID: 28771670 Free article. No abstract available.
Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D. El-Galaly TC, et al. Among authors: cecchetti c. Eur J Cancer. 2018 Apr;93:57-68. doi: 10.1016/j.ejca.2018.01.073. Epub 2018 Feb 21. Eur J Cancer. 2018. PMID: 29477102 Free PMC article.
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
Ferreri AJM, Sassone M, Angelillo P, Zaja F, Re A, Di Rocco A, Spina M, Fabbri A, Stelitano C, Frezzato M, Volpetti S, Zambello R, Rusconi C, De Lorenzo D, Scarano E, Arcari A, Bertoldero G, Nonis A, Calimeri T, Perrone S, Cecchetti C, Tarantino V, Steffanoni S, Foppoli M, Ciceri F, Ponzoni M. Ferreri AJM, et al. Among authors: cecchetti c. Hematol Oncol. 2020 Aug;38(3):257-265. doi: 10.1002/hon.2742. Epub 2020 May 5. Hematol Oncol. 2020. PMID: 32356913 Clinical Trial.
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.
Ferreri AJM, Calimeri T, Conte GM, Cattaneo D, Fallanca F, Ponzoni M, Scarano E, Curnis F, Nonis A, Lopedote P, Citterio G, Politi LS, Foppoli M, Girlanda S, Sassone M, Perrone S, Cecchetti C, Ciceri F, Bordignon C, Corti A, Anzalone N. Ferreri AJM, et al. Among authors: cecchetti c. Blood. 2019 Jul 18;134(3):252-262. doi: 10.1182/blood.2019000633. Epub 2019 May 22. Blood. 2019. PMID: 31118164 Free article. Clinical Trial.
127 results